A pharmaceutical agent that lowers blood LDL and has the action of suppressing the expression of PCSK9 mRNA, lowering the amount of PCSK9 protein, and increasing the amount of LDL receptor (R1 is a hydrogen atom, a hydroxyl group, C1- 6 represents an alkoxy group, R represents a C1-6 alkyl group, etc., and in formula (I), the ring structure represented by Q represents a phenyl group or a monocyclic or bicyclic heterocyclic ring, R2, And R3 represents a hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C3-8 cycloalkyl C1-6 alkyl group or the like).血中ＬＤＬを低下させる医薬であって、ＰＣＳＫ９ｍＲＮＡの発現を抑制し、ＰＣＳＫ９タンパク量を低下させ、ＬＤＬ受容体量を増加させる作用を有する式（I）（Ｒ１は、水素原子、水酸基、Ｃ１－６アルコキシ基等を示し、ＲはＣ１－６アルキル基等を示し、式（I）中、Ｑで表される環構造はフェニル基若しくは単環性又は二環性の複素環を示し、Ｒ２、及びＲ３は水素原子、Ｃ１－６アルキル基、Ｃ２－６アルケニル基、Ｃ３－８シクロアルキルＣ１－６アルキル基等を示す）で表される化合物を有効成分として含む医薬。
